SlideShare a Scribd company logo
1 of 31
[object Object]
Introduction ,[object Object]
OSTEOPOROSIS ,[object Object]
Age-related loss of trabecular bone
[object Object],[object Object]
Functions of the Vitamin D Endocrine System
Introduction ,[object Object],[object Object],[object Object]
Schematic diagram of the human vitamin D receptor gene
Aim of Work ,[object Object]
PATIENTS AND METHODS ,[object Object],[object Object]
Identification of Vit. D receptor [FOKI, BSMI] polymorphism by PCR technique followed by RFLP analysis ,[object Object],[object Object],[object Object]
DNA Amplification with the Polymerase Chain Reaction (PCR) Make copies ( extend primers ) Starting DNA Template 5’ 5’ 3’ 3’ 5’ 5’ 3’ 3’ Add primers ( anneal ) 5’ 3’ 3’ 5’ Forward primer Reverse primer Separate strands ( denature ) 5’ 5’ 3’ 3’
In 35 cycles at 100% efficiency, 1.07 billion copies of targeted DNA region are created PCR Copies DNA through Multiple Thermal Cycles Original DNA target region Thermal cycle Thermal cycle Thermal cycle
Mutation detection by restriction analysis 7  6  5  4  3  2  1  Ladder   69 bp-- 196 bp-- 265 bp--
7  6  5  4  3  2  1  Ladder 69 bp-- 196 bp-- 265 bp--
8  7  6  5  4  3  2  1  Ladder   200 bp 650 bp  850 bp
RESULTS
Body mass index of osteoporotic and controls
Distribution of different genotypes of FOKI polymorphism & alleles frequency in patients & controls:   FF genotype Ff genotype ff  genotype Allele (%) F  f Patients (n=50) N (%) 34 (68) 9 (18) 7 (14) 72.9  27.1 Controls (n=20) N (%) 20 (100) 0 (0) 0 (0) 100 0
Distribution of different genotypes of BSMI polymorphism & alleles frequency in patients & controls:   BB genotype Bb genotype bb  genotype Allele (%) B  b Patients (n=50) N (%) 27 (54) 15 (30) 8 (16) 64.6  35.4 Controls (n=20) N (%) 1 (5) 2 (10) 17 (85) 13.6 86.4
Comparison of the studied parameters in FOKI   0.07 0.68±.088 .74 ± .140 BMD lumbar (g/cm 2 ) 0.000 0.68±.040 0.77 ± .129 BMD femoral (g/cm 2 ) 0.04 -2.11 ±0 .91 -1.54 ±  1.14 T score lumbar 0.3 -1.21 ± 1.14 -.94  ±  .983 T scorefemoral P-value Ff+ff (N=16) Mean ± SD FF (N=54) Mean ± SD Variables
BMD lumbar of osteoporotic patients
Comparison of the studied parameters in BSMI 0.000 0.67±0.10 0.84 ± 0.11 BMD lumbar (g/cm 2 ) 0.000 0.70 ±0 .07 0.85  ±0 .13 BMD femoral (g/cm 2 ) 0.001 -2.00 ± 1.02 -1.08 ±  1.05 T score lumbar 0.10 -1.14 ± 1.06 -0.75  ± 0 .92 T scorefemoral P-value Bb+bb (N=45) Mean ± SD bb (N=25) Mean ± SD Variables
BMD lumbar of osteoporotic patients
Combined genotypes of BSMI and FOKI  of osteoporotic patients
Combined genotype of BSMI and FOKI of controls
O.R ratio of FOK1genotypes of patients and controls:     (32) (0) (%)   16 0 Count Ff+ff   (68) (100) (%)   1.588(1.29-1.95)  0.004 34 20 Count FF   cases control FOK1   OR (95% CI) P value GROUP
O.R ratio of BSM1 genotypes of patients and controls: (16) (85) (%) 8 17 Count bb (84) (15) (% ) 29.75(7.04-125.8)  0.000 42 3 Count BB+Bb cases control BSM1
Conclusion  ,[object Object]
[object Object]
Thank you

More Related Content

What's hot

Cell Metabolism Part 1
Cell Metabolism Part 1Cell Metabolism Part 1
Cell Metabolism Part 1
raj kumar
 
Glucosamine Chondroitin Sulfate Dietary Supplement for Osteoarthritis
Glucosamine Chondroitin Sulfate Dietary Supplement for OsteoarthritisGlucosamine Chondroitin Sulfate Dietary Supplement for Osteoarthritis
Glucosamine Chondroitin Sulfate Dietary Supplement for Osteoarthritis
W3llness
 
7 29-10enzymeskinetics-coloso-110715062024-phpapp01[1]
7 29-10enzymeskinetics-coloso-110715062024-phpapp01[1]7 29-10enzymeskinetics-coloso-110715062024-phpapp01[1]
7 29-10enzymeskinetics-coloso-110715062024-phpapp01[1]
Khamees Faraj
 

What's hot (20)

Collagen
CollagenCollagen
Collagen
 
History of enzymes.
History of enzymes.History of enzymes.
History of enzymes.
 
Weaver Molecular Biology 5th ed Chapter.1 presentation
Weaver Molecular Biology 5th ed Chapter.1 presentationWeaver Molecular Biology 5th ed Chapter.1 presentation
Weaver Molecular Biology 5th ed Chapter.1 presentation
 
Probiotics
ProbioticsProbiotics
Probiotics
 
Disorders of lipid metabolism case studies-1
Disorders of lipid metabolism  case studies-1Disorders of lipid metabolism  case studies-1
Disorders of lipid metabolism case studies-1
 
Nutrigenomics
NutrigenomicsNutrigenomics
Nutrigenomics
 
Protein
ProteinProtein
Protein
 
Managing histamine intolerance
Managing histamine intoleranceManaging histamine intolerance
Managing histamine intolerance
 
GALACTOSE AND FRUCTOSE(2).pptx
GALACTOSE AND FRUCTOSE(2).pptxGALACTOSE AND FRUCTOSE(2).pptx
GALACTOSE AND FRUCTOSE(2).pptx
 
Cell Metabolism Part 1
Cell Metabolism Part 1Cell Metabolism Part 1
Cell Metabolism Part 1
 
Nutrigenomics
NutrigenomicsNutrigenomics
Nutrigenomics
 
Nutrition in Cancer Prevention and Treatment
Nutrition in Cancer Prevention and TreatmentNutrition in Cancer Prevention and Treatment
Nutrition in Cancer Prevention and Treatment
 
Protein structure and disease
Protein structure and diseaseProtein structure and disease
Protein structure and disease
 
Glucosamine Chondroitin Sulfate Dietary Supplement for Osteoarthritis
Glucosamine Chondroitin Sulfate Dietary Supplement for OsteoarthritisGlucosamine Chondroitin Sulfate Dietary Supplement for Osteoarthritis
Glucosamine Chondroitin Sulfate Dietary Supplement for Osteoarthritis
 
Adiponectin
AdiponectinAdiponectin
Adiponectin
 
Complex lipids (phosholipid) structure & function
Complex lipids (phosholipid) structure & functionComplex lipids (phosholipid) structure & function
Complex lipids (phosholipid) structure & function
 
TOXICOLOGY OF FOOD ADDITIVES.pptx
TOXICOLOGY OF FOOD ADDITIVES.pptxTOXICOLOGY OF FOOD ADDITIVES.pptx
TOXICOLOGY OF FOOD ADDITIVES.pptx
 
7 29-10enzymeskinetics-coloso-110715062024-phpapp01[1]
7 29-10enzymeskinetics-coloso-110715062024-phpapp01[1]7 29-10enzymeskinetics-coloso-110715062024-phpapp01[1]
7 29-10enzymeskinetics-coloso-110715062024-phpapp01[1]
 
Inborn errors of lipid metabolism
Inborn errors of lipid metabolismInborn errors of lipid metabolism
Inborn errors of lipid metabolism
 
Nutrigenomics
NutrigenomicsNutrigenomics
Nutrigenomics
 

Viewers also liked

NRAMP1 and VDR Gene Polymorphisms in Susceptibility to Tuberculosis in Venezu...
NRAMP1 and VDR Gene Polymorphisms in Susceptibility to Tuberculosis in Venezu...NRAMP1 and VDR Gene Polymorphisms in Susceptibility to Tuberculosis in Venezu...
NRAMP1 and VDR Gene Polymorphisms in Susceptibility to Tuberculosis in Venezu...
Universidad Central de Venezuela
 
Delaying Osteoporosis in Early Postmenopausal Women: Exercise as the New Medi...
Delaying Osteoporosis in Early Postmenopausal Women: Exercise as the New Medi...Delaying Osteoporosis in Early Postmenopausal Women: Exercise as the New Medi...
Delaying Osteoporosis in Early Postmenopausal Women: Exercise as the New Medi...
Bond University HSM Faculty
 
Common reproductive health conditions
Common reproductive health conditionsCommon reproductive health conditions
Common reproductive health conditions
Jen Gragera
 

Viewers also liked (20)

The role of vitamin d in reducing cancer risk and progression
The role of vitamin d in reducing cancer risk and progressionThe role of vitamin d in reducing cancer risk and progression
The role of vitamin d in reducing cancer risk and progression
 
NRAMP1 and VDR Gene Polymorphisms in Susceptibility to Tuberculosis in Venezu...
NRAMP1 and VDR Gene Polymorphisms in Susceptibility to Tuberculosis in Venezu...NRAMP1 and VDR Gene Polymorphisms in Susceptibility to Tuberculosis in Venezu...
NRAMP1 and VDR Gene Polymorphisms in Susceptibility to Tuberculosis in Venezu...
 
Delaying Osteoporosis in Early Postmenopausal Women: Exercise as the New Medi...
Delaying Osteoporosis in Early Postmenopausal Women: Exercise as the New Medi...Delaying Osteoporosis in Early Postmenopausal Women: Exercise as the New Medi...
Delaying Osteoporosis in Early Postmenopausal Women: Exercise as the New Medi...
 
Common reproductive health conditions
Common reproductive health conditionsCommon reproductive health conditions
Common reproductive health conditions
 
184 toll like receptor 4 and atherosclerosis
184 toll like receptor 4 and atherosclerosis184 toll like receptor 4 and atherosclerosis
184 toll like receptor 4 and atherosclerosis
 
Pathways07 tlr
Pathways07 tlrPathways07 tlr
Pathways07 tlr
 
Immunisatie1
Immunisatie1Immunisatie1
Immunisatie1
 
The Effects Of Soy Isoflavone On Bone Mineral Density In Pre And Postmenopau...
The Effects Of Soy Isoflavone On Bone Mineral Density In Pre  And Postmenopau...The Effects Of Soy Isoflavone On Bone Mineral Density In Pre  And Postmenopau...
The Effects Of Soy Isoflavone On Bone Mineral Density In Pre And Postmenopau...
 
Receptores tipo toll y obesidad
Receptores tipo toll y obesidadReceptores tipo toll y obesidad
Receptores tipo toll y obesidad
 
TLR - Kashmeera
TLR - KashmeeraTLR - Kashmeera
TLR - Kashmeera
 
Toll-like Receptors in Inflammation: Host Defense Webinar Series Part 2
Toll-like Receptors in Inflammation: Host Defense Webinar Series Part 2Toll-like Receptors in Inflammation: Host Defense Webinar Series Part 2
Toll-like Receptors in Inflammation: Host Defense Webinar Series Part 2
 
TLR -Toll Like Receptors
TLR -Toll Like ReceptorsTLR -Toll Like Receptors
TLR -Toll Like Receptors
 
Pathogen recognition
Pathogen recognitionPathogen recognition
Pathogen recognition
 
Toll like receptors
Toll like receptorsToll like receptors
Toll like receptors
 
Postmenopausal osteoporosis
Postmenopausal osteoporosis Postmenopausal osteoporosis
Postmenopausal osteoporosis
 
TLR
TLRTLR
TLR
 
Toll like receptors
Toll like receptors   Toll like receptors
Toll like receptors
 
Innate Immunity
Innate ImmunityInnate Immunity
Innate Immunity
 
Innate immunity
Innate immunityInnate immunity
Innate immunity
 
polymorphism
polymorphism polymorphism
polymorphism
 

Similar to Pattern of vitamin d receptor polymorphism

Association Study of Single Nucleotide Polymorphism of PTH Gene in Osteopor...
Association Study of Single  Nucleotide Polymorphism of PTH  Gene in Osteopor...Association Study of Single  Nucleotide Polymorphism of PTH  Gene in Osteopor...
Association Study of Single Nucleotide Polymorphism of PTH Gene in Osteopor...
Alia Iqniebi
 
Lunch session p lakatos
Lunch session p lakatosLunch session p lakatos
Lunch session p lakatos
Asszisztencia
 
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silentWay+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
dhavalshah4424
 
Vitamin D and Bone Health
Vitamin D and Bone HealthVitamin D and Bone Health
Vitamin D and Bone Health
demiss
 

Similar to Pattern of vitamin d receptor polymorphism (20)

Association Study of Single Nucleotide Polymorphism of PTH Gene in Osteopor...
Association Study of Single  Nucleotide Polymorphism of PTH  Gene in Osteopor...Association Study of Single  Nucleotide Polymorphism of PTH  Gene in Osteopor...
Association Study of Single Nucleotide Polymorphism of PTH Gene in Osteopor...
 
Integrating TBS Into Your Clinical Practice.pdf
Integrating TBS Into Your Clinical Practice.pdfIntegrating TBS Into Your Clinical Practice.pdf
Integrating TBS Into Your Clinical Practice.pdf
 
Hormonal Causes of Secondary Osteoporosis
Hormonal Causes of Secondary OsteoporosisHormonal Causes of Secondary Osteoporosis
Hormonal Causes of Secondary Osteoporosis
 
Lunch session p lakatos
Lunch session p lakatosLunch session p lakatos
Lunch session p lakatos
 
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silentWay+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
Way+forward+in+osteoporosis%3aa+disease+which+is+no+longer+silent
 
Multiple Myeloma.pptx
Multiple Myeloma.pptxMultiple Myeloma.pptx
Multiple Myeloma.pptx
 
Prevalence of osteoporosis in 100 iraqi patients with systemic
Prevalence of osteoporosis in 100 iraqi patients with systemicPrevalence of osteoporosis in 100 iraqi patients with systemic
Prevalence of osteoporosis in 100 iraqi patients with systemic
 
Osteoporosis 2016 | Diabetes and bone: Prof. Serge Ferrari #osteo2016
Osteoporosis 2016 | Diabetes and bone: Prof. Serge Ferrari #osteo2016Osteoporosis 2016 | Diabetes and bone: Prof. Serge Ferrari #osteo2016
Osteoporosis 2016 | Diabetes and bone: Prof. Serge Ferrari #osteo2016
 
Vitamin D and Bone Health
Vitamin D and Bone HealthVitamin D and Bone Health
Vitamin D and Bone Health
 
ECCLU 2011 - N. Clarke - Bone targeted agents
ECCLU 2011 - N. Clarke - Bone targeted agentsECCLU 2011 - N. Clarke - Bone targeted agents
ECCLU 2011 - N. Clarke - Bone targeted agents
 
Osteoporosis
OsteoporosisOsteoporosis
Osteoporosis
 
Ruth Loos-Lo último en obesidad
Ruth Loos-Lo último en obesidadRuth Loos-Lo último en obesidad
Ruth Loos-Lo último en obesidad
 
Osteoporosis 2016 | DXA and beyond: Dr Nicola Crabtree #osteo2016
Osteoporosis 2016 | DXA and beyond: Dr Nicola Crabtree #osteo2016Osteoporosis 2016 | DXA and beyond: Dr Nicola Crabtree #osteo2016
Osteoporosis 2016 | DXA and beyond: Dr Nicola Crabtree #osteo2016
 
Osteoporosis, Diagnosis and treatment
Osteoporosis, Diagnosis and treatmentOsteoporosis, Diagnosis and treatment
Osteoporosis, Diagnosis and treatment
 
Seminar 22-11-2014 Prof. Dr. W.F. Lems - Highlights ASBMR
Seminar 22-11-2014 Prof. Dr. W.F. Lems - Highlights ASBMRSeminar 22-11-2014 Prof. Dr. W.F. Lems - Highlights ASBMR
Seminar 22-11-2014 Prof. Dr. W.F. Lems - Highlights ASBMR
 
Osteoporosis%203rd%20yr[1]
Osteoporosis%203rd%20yr[1]Osteoporosis%203rd%20yr[1]
Osteoporosis%203rd%20yr[1]
 
IWO bijeenkomst - 14 november - Dr. F. Malgo
IWO bijeenkomst - 14 november - Dr. F. MalgoIWO bijeenkomst - 14 november - Dr. F. Malgo
IWO bijeenkomst - 14 november - Dr. F. Malgo
 
Vitamin D and Multiple Sclerosis
Vitamin D and Multiple SclerosisVitamin D and Multiple Sclerosis
Vitamin D and Multiple Sclerosis
 
Management of osteoporosis
Management of osteoporosisManagement of osteoporosis
Management of osteoporosis
 
Seminar 28-11-2015 Prof. Dr. W.F. Lems
Seminar 28-11-2015 Prof. Dr. W.F. LemsSeminar 28-11-2015 Prof. Dr. W.F. Lems
Seminar 28-11-2015 Prof. Dr. W.F. Lems
 

More from Hesham Gaber (20)

Management of poor ovarian response
Management of poor ovarian responseManagement of poor ovarian response
Management of poor ovarian response
 
High responders
High respondersHigh responders
High responders
 
Prognostic models
Prognostic modelsPrognostic models
Prognostic models
 
GnRH antagonists
GnRH antagonistsGnRH antagonists
GnRH antagonists
 
Poor
PoorPoor
Poor
 
Infertility
InfertilityInfertility
Infertility
 
So much evidence 1
So much evidence 1So much evidence 1
So much evidence 1
 
So much evidence 1
So much evidence 1So much evidence 1
So much evidence 1
 
Contraception
ContraceptionContraception
Contraception
 
Management of poor ovarian response
Management of poor ovarian responseManagement of poor ovarian response
Management of poor ovarian response
 
Thromboprophylaxis
ThromboprophylaxisThromboprophylaxis
Thromboprophylaxis
 
So much evidence
So much evidenceSo much evidence
So much evidence
 
Why to know statistics
Why to know statisticsWhy to know statistics
Why to know statistics
 
Uterine sarcoma
Uterine sarcomaUterine sarcoma
Uterine sarcoma
 
Systematic review
Systematic reviewSystematic review
Systematic review
 
Statistics & infertility
Statistics & infertilityStatistics & infertility
Statistics & infertility
 
Research methodology 101
Research methodology 101Research methodology 101
Research methodology 101
 
Randomised controlled trials
Randomised controlled trialsRandomised controlled trials
Randomised controlled trials
 
Paternal age
Paternal agePaternal age
Paternal age
 
Ovarian hyperstimulation syndrome
Ovarian hyperstimulation syndromeOvarian hyperstimulation syndrome
Ovarian hyperstimulation syndrome
 

Recently uploaded

Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businessWhy Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
panagenda
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Safe Software
 
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Victor Rentea
 
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
?#DUbAI#??##{{(☎️+971_581248768%)**%*]'#abortion pills for sale in dubai@
 
Architecting Cloud Native Applications
Architecting Cloud Native ApplicationsArchitecting Cloud Native Applications
Architecting Cloud Native Applications
WSO2
 

Recently uploaded (20)

CNIC Information System with Pakdata Cf In Pakistan
CNIC Information System with Pakdata Cf In PakistanCNIC Information System with Pakdata Cf In Pakistan
CNIC Information System with Pakdata Cf In Pakistan
 
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businessWhy Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
 
Six Myths about Ontologies: The Basics of Formal Ontology
Six Myths about Ontologies: The Basics of Formal OntologySix Myths about Ontologies: The Basics of Formal Ontology
Six Myths about Ontologies: The Basics of Formal Ontology
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
WSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering DevelopersWSO2's API Vision: Unifying Control, Empowering Developers
WSO2's API Vision: Unifying Control, Empowering Developers
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of Terraform
 
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024Finding Java's Hidden Performance Traps @ DevoxxUK 2024
Finding Java's Hidden Performance Traps @ DevoxxUK 2024
 
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ..."I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
 
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, AdobeApidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
 
Introduction to use of FHIR Documents in ABDM
Introduction to use of FHIR Documents in ABDMIntroduction to use of FHIR Documents in ABDM
Introduction to use of FHIR Documents in ABDM
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
 
Strategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a FresherStrategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a Fresher
 
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
 
MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024MINDCTI Revenue Release Quarter One 2024
MINDCTI Revenue Release Quarter One 2024
 
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
Apidays New York 2024 - Accelerating FinTech Innovation by Vasa Krishnan, Fin...
 
Corporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptxCorporate and higher education May webinar.pptx
Corporate and higher education May webinar.pptx
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century education
 
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWEREMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
EMPOWERMENT TECHNOLOGY GRADE 11 QUARTER 2 REVIEWER
 
Architecting Cloud Native Applications
Architecting Cloud Native ApplicationsArchitecting Cloud Native Applications
Architecting Cloud Native Applications
 

Pattern of vitamin d receptor polymorphism

  • 1.
  • 2.
  • 3.
  • 4. Age-related loss of trabecular bone
  • 5.
  • 6. Functions of the Vitamin D Endocrine System
  • 7.
  • 8. Schematic diagram of the human vitamin D receptor gene
  • 9.
  • 10.
  • 11.
  • 12. DNA Amplification with the Polymerase Chain Reaction (PCR) Make copies ( extend primers ) Starting DNA Template 5’ 5’ 3’ 3’ 5’ 5’ 3’ 3’ Add primers ( anneal ) 5’ 3’ 3’ 5’ Forward primer Reverse primer Separate strands ( denature ) 5’ 5’ 3’ 3’
  • 13. In 35 cycles at 100% efficiency, 1.07 billion copies of targeted DNA region are created PCR Copies DNA through Multiple Thermal Cycles Original DNA target region Thermal cycle Thermal cycle Thermal cycle
  • 14. Mutation detection by restriction analysis 7 6 5 4 3 2 1 Ladder 69 bp-- 196 bp-- 265 bp--
  • 15. 7 6 5 4 3 2 1 Ladder 69 bp-- 196 bp-- 265 bp--
  • 16. 8 7 6 5 4 3 2 1 Ladder 200 bp 650 bp 850 bp
  • 18. Body mass index of osteoporotic and controls
  • 19. Distribution of different genotypes of FOKI polymorphism & alleles frequency in patients & controls: FF genotype Ff genotype ff genotype Allele (%) F f Patients (n=50) N (%) 34 (68) 9 (18) 7 (14) 72.9 27.1 Controls (n=20) N (%) 20 (100) 0 (0) 0 (0) 100 0
  • 20. Distribution of different genotypes of BSMI polymorphism & alleles frequency in patients & controls: BB genotype Bb genotype bb genotype Allele (%) B b Patients (n=50) N (%) 27 (54) 15 (30) 8 (16) 64.6 35.4 Controls (n=20) N (%) 1 (5) 2 (10) 17 (85) 13.6 86.4
  • 21. Comparison of the studied parameters in FOKI 0.07 0.68±.088 .74 ± .140 BMD lumbar (g/cm 2 ) 0.000 0.68±.040 0.77 ± .129 BMD femoral (g/cm 2 ) 0.04 -2.11 ±0 .91 -1.54 ± 1.14 T score lumbar 0.3 -1.21 ± 1.14 -.94 ± .983 T scorefemoral P-value Ff+ff (N=16) Mean ± SD FF (N=54) Mean ± SD Variables
  • 22. BMD lumbar of osteoporotic patients
  • 23. Comparison of the studied parameters in BSMI 0.000 0.67±0.10 0.84 ± 0.11 BMD lumbar (g/cm 2 ) 0.000 0.70 ±0 .07 0.85 ±0 .13 BMD femoral (g/cm 2 ) 0.001 -2.00 ± 1.02 -1.08 ± 1.05 T score lumbar 0.10 -1.14 ± 1.06 -0.75 ± 0 .92 T scorefemoral P-value Bb+bb (N=45) Mean ± SD bb (N=25) Mean ± SD Variables
  • 24. BMD lumbar of osteoporotic patients
  • 25. Combined genotypes of BSMI and FOKI of osteoporotic patients
  • 26. Combined genotype of BSMI and FOKI of controls
  • 27. O.R ratio of FOK1genotypes of patients and controls:   (32) (0) (%)   16 0 Count Ff+ff   (68) (100) (%)   1.588(1.29-1.95) 0.004 34 20 Count FF   cases control FOK1   OR (95% CI) P value GROUP
  • 28. O.R ratio of BSM1 genotypes of patients and controls: (16) (85) (%) 8 17 Count bb (84) (15) (% ) 29.75(7.04-125.8) 0.000 42 3 Count BB+Bb cases control BSM1
  • 29.
  • 30.

Editor's Notes

  1. extraction of DNA using salting out technique followed by amplification of extracted DNA at exon 2 for FOKI & intron 8 for BSMI and amplified DNA was then cut by restriction enzyme FOKI for detection of FOKI polymorphism and by enzyme BSMI for detection of BSMI polymorphism and then electrophoresis of the DNA was done on agarose gel.